Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Folinic Acid→

Folinic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58-05-9
Molecular formula
C20H23N7O7
Molecular weight
473.4 g/mol
Drug class
Leucovorin (5-formyltetrahydrofolate)reduced folate analogue and folate rescue agent
Mechanism of action
Provides reduced folate downstream of dihydrofolate reductase, bypassing DHFR blockade and restoring tetrahydrofolate pools. It also potentiates fluorouracil by stabilising the thymidylate synthase–FdUMP complex.
Indications / reported uses
  • Rescue after high-dose methotrexate therapy and treatment of folate-antagonist toxicity
  • In combination with fluorouracil to enhance antitumour activity in colorectal cancer regimens
  • Treatment of selected megaloblastic anaemias due to folate deficiency when parenteral therapy is needed; not a substitute for folic acid in routine prevention

Sources: US DailyMed — Leucovorin calcium · NLM MeSH — Folinic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Folinic Acid Environmental Risk Assessment (ERA) (the Folinic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.